A. Tanimoto

发表

The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling.

T. Dainichi, T. Honda, K. Kabashima, 2015, The Journal of allergy and clinical immunology.

Participation of prostaglandin E2 and platelet-activating factor in thapsigargin-induced production of interleukin-6.

K. Ohuchi, A. Tanimoto, H. Yaginuma, 2002, European journal of pharmacology.

Inhibition of tumor necrosis factor-α production by SK&F 98625, a CoA-independent transacylase inhibitor, in cultured rat peritoneal macrophages

K. Ohuchi, A. Tanimoto, H. Yaginuma, 1998 .

JTA-009, a fully human antibody against human AILIM/ICOS, ameliorates graft-vs-host reaction in SCID mice grafted with human PBMCs.

K. Tezuka, N. Tajima, Yoshihiro Watanabe, 2008, Experimental hematology.

Possible participation of intracellular platelet-activating factor in NF-kappaB activation in rat peritoneal macrophages.

K. Ohuchi, A. Tanimoto, H. Yaginuma, 2002, Biochimica et biophysica acta.

JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation.

K. Kabashima, Y. Miyachi, M. Matsushita, 2016, Journal of dermatological science (Amsterdam).

A novel JAK inhibitor JTE‐052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents

Y. Katsuda, Y. Shinozaki, Wataru Amano, 2018, Experimental dermatology.

Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.

T. Honda, K. Kabashima, K. Usui, 2019, Journal of dermatological science.

Surgical Strategy for Sylvian Fissure Arteriovenous Malformations

S. Hamano, S. Fujita, T. Kawaguchi, 1993 .

Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.

Hiroshi Yamamoto, S. Noji, Hiromasa Hashimoto, 2020, Journal of medicinal chemistry.

Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo

S. Noji, Makoto Shiozaki, Yoshihiro Ogawa, 2014, Inflammation Research.

Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction.

K. Aoyagi, Y. Hantani, H. Yamanaka, 2019, Bioorganic & medicinal chemistry letters.

Possible participation of intracellular platelet-activating factor in tumor necrosis factor-alpha production by rat peritoneal macrophages.

K. Ohuchi, A. Tanimoto, H. Yaginuma, 1999, European journal of pharmacology.

Neuropsychological Impairment of the Patients Who Recovered Social Life after Surgery for the Ruptured Anterior Communicating Artery Aneurysm.

N. Tamaki, K. Ehara, T. Kawaguchi, 2002 .

Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis

M. Matsushita, Keisuke Nozawa, Takayuki Yamaguchi, 2015, BMC Musculoskeletal Disorders.

Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide

Takayuki Yamaguchi, Reina Kakefuda, N. Tajima, 2012, Inflammation Research.

SAR study of small molecule inhibitors of the programmed cell death‐1/programmed cell death‐ligand 1 interaction

K. Aoyagi, Y. Hantani, H. Yamanaka, 2021, Chemical biology & drug design.

JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation.

K. Kabashima, Y. Miyachi, M. Matsushita, 2016, Journal of dermatological science.

518 The effect of janus kinase inhibitor on pruritus in an atopic dermatitis murine model

K. Kabashima, A. Otsuka, C. Nakashima, 2016 .